1. Home
  2. GCBC vs ANL Comparison

GCBC vs ANL Comparison

Compare GCBC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greene County Bancorp Inc.

GCBC

Greene County Bancorp Inc.

HOLD

Current Price

$33.56

Market Cap

590.1M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$12.66

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCBC
ANL
Founded
1889
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
590.1M
611.1M
IPO Year
1998
2022

Fundamental Metrics

Financial Performance
Metric
GCBC
ANL
Price
$33.56
$12.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
43.9K
249.9K
Earning Date
04-22-2026
04-10-2026
Dividend Yield
1.66%
N/A
EPS Growth
26.21
N/A
EPS
1.74
N/A
Revenue
$4,117,000.00
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
N/A
N/A
P/E Ratio
$18.97
N/A
Revenue Growth
11.06
N/A
52 Week Low
$21.25
$0.88
52 Week High
$36.02
$17.25

Technical Indicators

Market Signals
Indicator
GCBC
ANL
Relative Strength Index (RSI) 61.48 54.70
Support Level $31.52 $11.86
Resistance Level $33.99 $12.24
Average True Range (ATR) 1.20 1.14
MACD -0.23 0.31
Stochastic Oscillator 42.67 68.40

Price Performance

Historical Comparison
GCBC
ANL

About GCBC Greene County Bancorp Inc.

Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: